GSK is a global biopharma company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. GSK’s lead drug candidate, momelotinib, is an orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor. More than 1,200 subjects have received momelotinib in clinical trials, where it has demonstrated a potentially differentiated therapeutic profile in myelofibrosis. GSK is running the MOMENTUM Phase 3 clinical trial, a randomized double-blind trial designed to enroll 180 myelofibrosis patients previously treated with a JAK inhibitor. Momelotinib will be evaluated on endpoints including constitutional symptoms, anemia benefits (including eliminating or reducing the need for frequent blood transfusions), and spleen control. Dr. Srdan Verstovsek, The University of Texas MD Anderson Cancer Center, is Chief Investigator of the MOMENTUM trial. The FDA has granted momelotinib Fast Track designation, learn more.